Back to Trades
Other4
Mural Oncology plc
MURA
Total Value
$712.5K
Company Information
- Company Name
- Mural Oncology plc
- Ticker Symbol
- MURA
- CIK
- 0001971543
Insider Information
- Name
- Goodman Vicki L
- Role
- Insider
- Location
- DUBLIN 2, L2
Filing Details
- Filing Date
- Dec 5, 2025
- Transaction Date
- Dec 5, 2025
- Accession Number
- 0001193125-25-308745
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Dec 5, 2025 | Ordinary Shares | 84,727 | — | Disposition | — |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Dec 5, 2025 | Derivative | 135,604 | $3.61 | Disposition | $489.5K |
| Dec 5, 2025 | Derivative | 65,000 | $3.43 | Disposition | $222.9K |
Footnotes
- (F1)Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time").
- (F2)Includes the disposition of 71,509 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration.
- (F3)Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.